The TUDCA ALS consortium, funded through a € 5.6 million funding grant from the European Commission Horizon 2020 Programme, started on 1st January 2018.
TUDCA-ALS has assembled and integrated a network of Europe’s 10 most talented and esteemed academic re-searchers from partner institutions in seven EU countries including the Italian Humanitas Mirasole SpA, the Istituto Superiore di Sanità and SME pharma company Bruschettini of Genoa, and several European academic centres: the University of Ulm (Germany), the University of Sheffield (United Kingdom), the University Hospital of Tours (France), the Catholic University of Leuven (Belgium), the University Medical Center of Utrecht (Netherlands), and Trinity College Dublin (Ireland). The Motor Neurone Disease Association (United Kingdom), is a partnering patient association confirming the primary role played by lay associations in this disease.
The “TUDCA-ALS project” includes the trial of a new drug treatment against Amyotrophic Lateral Sclerosis (ALS).
“The study, led by Humanitas, will last for four years and will allow us to evaluate the therapeutic efficacy of a new treatment for ALS, using a drug derived from bile acids, called Tauroursodeoxycholic Acid (TUDCA)” – said Prof. Alberto Albanese, Head of Neurology at of Humanitas.